North Hills (Pennsylvania)

Global Private LTE Market to Reach $6.258 Billion by 2027

Retrieved on: 
Thursday, August 4, 2022
Chief digital officer, NSA, USS Red Rover (1859), Western Canada Wilderness Committee, Hutchison Asia Telecom Group, Teck Resources, GSM, Technology, NTT, UMTS, Geography, Growth, IOT, APT, Creativity, Nokia, School, Acquisition, Robert Shaw (business writer), Partnership, North Hills (Pennsylvania), LTE, PMR, Shaw, CAGR, Red Rover, Ericsson, Telecom, Radio, Adoption, Mobile phone, Kajeet, Teck

DUBLIN, Aug. 4, 2022 /PRNewswire/ -- The "Private LTE Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Aug. 4, 2022 /PRNewswire/ -- The "Private LTE Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The private LTE market is projected to grow at a CAGR of 11.88% during the forecast period to reach US$6.258 billion by 2027, from US$2.852 billion in 2020.
  • The emergence of 5G, technological advancements, and a fiercely competitive landscape are expected to drive the private LTE market onward.
  • The deployment of private LTE networks by Teck Resources Limited and NLMK Groups' initiative to adopt a private LTE network into their facilities are the best examples of this.

Private LTE Market Report 2022: Emergence of 5G, Technological Advancements, and a Fiercely Competitive Landscape Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 3, 2022
Software, Technology, Networks, NSA, Ericsson, Shaw, Nokia, APT, Adoption, Western Canada Wilderness Committee, GSM, UMTS, Hutchison Asia Telecom Group, Partnership, Robert Shaw (business writer), Teck Resources, North Hills (Pennsylvania), Creativity, Chief digital officer, Technology, Radio, School, Red Rover, CAGR, PMR, Telecom, NTT, LTE, USS Red Rover (1859), Acquisition, Geography, IOT, Growth, Mobile phone, Teck, Kajeet

The emergence of 5G, technological advancements, and a fiercely competitive landscape are expected to drive the private LTE market onward.

Key Points: 
  • The emergence of 5G, technological advancements, and a fiercely competitive landscape are expected to drive the private LTE market onward.
  • This further opens up the potential to transition existing PMR/LMR clients to private LTE and then to private 5G networks later on.
  • The deployment of private LTE networks by Teck Resources Limited and NLMK Groups' initiative to adopt a private LTE network into their facilities are the best examples of this.
  • The growth of the private LTE market in this segment is attributed to the strategic developments deployed by key players in the region.

Antibe Therapeutics Provides Update on Otenaproxesul and Expanded Drug Pipeline

Retrieved on: 
Thursday, October 14, 2021
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Shift, Transparency, Incidence, Migraine, Nonsteroidal anti-inflammatory drug, IND, Pain, Observation, Ulcerative colitis, Bleeding, Antibe Therapeutics, Dysmenorrhea, IP, Architecture, GI, IBD, Phase, Aspirin, Ulcer, Ethernet Global Data Protocol, Osteoarthritis, TSX, Paracetamol, Inflammation, Patient, News, Hydrogen sulfide, OTCQX, Surgeon, Extrapyramidal system, Research, Â, Company, AME, Forward-looking statement, Pain management, Calendar, Review, Inflammatory bowel disease, Ketoprofen, Safety, Oxidative stress, Patent, Prescription, Therapy, III, North Hills (Pennsylvania), Pharmaceutical industry, Dietary supplement, Dentistry

Short-term pain management has its own considerable challenges, not the least being a continued reliance on opioids, for which otenaproxesul is an ideal fit.

Key Points: 
  • Short-term pain management has its own considerable challenges, not the least being a continued reliance on opioids, for which otenaproxesul is an ideal fit.
  • In collaboration with outside experts and key opinion leaders, the Company has completed a comprehensive assessment of the AME study data.
  • Antibes lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for acute pain and the treatment of osteoarthritis.
  • Antibe Therapeutics assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.